Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Inventory (2017 - 2025)

Puma Biotechnology's Inventory history spans 9 years, with the latest figure at $5.5 million for Q4 2025.

  • For Q4 2025, Inventory fell 36.78% year-over-year to $5.5 million; the TTM value through Dec 2025 reached $5.5 million, down 36.78%, while the annual FY2025 figure was $5.5 million, 36.78% down from the prior year.
  • Inventory reached $5.5 million in Q4 2025 per PBYI's latest filing, down from $9.5 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $9.5 million in Q3 2025 to a low of $2.7 million in Q3 2024.
  • Average Inventory over 5 years is $6.9 million, with a median of $7.2 million recorded in 2021.
  • Peak YoY movement for Inventory: crashed 52.93% in 2024, then soared 254.51% in 2025.
  • A 5-year view of Inventory shows it stood at $7.1 million in 2021, then tumbled by 36.33% to $4.5 million in 2022, then surged by 56.43% to $7.1 million in 2023, then grew by 23.22% to $8.7 million in 2024, then crashed by 36.78% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Inventory are $5.5 million (Q4 2025), $9.5 million (Q3 2025), and $8.6 million (Q2 2025).